CUMBERLAND, R.I.--(BUSINESS WIRE)--Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, today announced that it has filed an Investigational New Drug (“IND”) for its patent pending abuse deterrent sustained release opioid formulation COL-003. This follows a pre-IND meeting that the Company held with the FDA in March 2007 at which time the Company received guidance on the basis of approval requirements for the product. Collegium intends to commence its clinical development program immediately upon the acceptance of the IND by the FDA. Based upon feedback from the FDA, the product will likely qualify for fast track review status due to the potential public health benefit of the product regarding intentional and unintentional overdose.
